Phase II Study of PEND Chemotherapy in Patients with Refractory/Relapsed Hodgkin Lymphoma

References

• Bodis, S., Henry-Amar, M., Bosq, J., Burgers, J.M., Mellink, W.A., Dietrich, P.Y., et al. (1993) "Late relapse in early-stage Hodgkin's disease patients enrolled on European Organization for Research and Treatment of Cancer protocols", Journal of Clinical Oncology, 11, 225–232.
   PubMed Web of Science ®Google Scholar
• Fisher, RI., DeVita, V.T., Hubbard, S.P., Simon, R. and Young, R.C. (1979) "Prolonged disease-free survival in Hodgkin's disease with MOPP reinduction after first relapse", Annals of Internal Medicine, 90, 761 — 763.
   Google Scholar
• Longo, DL., Duffey, P.L., Young, R.C., Hubbard, S.M., Ihde, D.C., Glatstein, E., et al. (1992) "Conventional-dose salvage combination chemotherapy in patients relapsing with Hodgkin's disease after combination chemotherapy: the low probability for cure", Journal of Clinical Oncology, 10, 210— 218.
   PubMed Web of Science ®Google Scholar
• Constans, M., Sureda, A., Terol, Mi., Arranz, R., Caballero, M.D., Iriondo, A., et al. (2003) "Autologous stem cell transplantation for primary refractory Hodgkin's disease: results and clinical variables affecting outcome", Annals of Oncology, 14, 745–751.
   PubMed Web of Science ®Google Scholar
• Akpek, G., Ambinder, R.F., Piantadosi, S., Abrams, R.A., Brodsky, R.A., Vogelsang, GB., et al. (2001) "Long-term results of blood and marrow transplantation for Hodgkin's lymphoma", Journal of Clinical Oncology, 19, 4314–4321.
   Google Scholar
• Armitage, J.O., Bierman, P.J., Vose, J.M., Anderson, J.R., Weisenburger, D.D., Kessinger, A., et al. (1991) "Autologous bone marrow transplantation for patients with relapsed Hodgkin's disease", American Journal of Medicine, 91, 605 —611.
   Google Scholar
• Bierman, P.J., Bagin, R.G., Jagannath, S., Vose, J.M., Spitzer, G., Kessinger, A., et al. (1993) "High dose chemotherapy followed by autologous hematopoietic rescue in Hodgkin's disease: long-term follow-up in 128 patients", Annals of Oncology, 4, 767–773.
   Google Scholar
• Chopra, R., McMillan, AK., Linch, D.C., Yuklea, S., Taghipour, G., Pearce, R., et al. (1993) "The place of high-dose BEAM therapy and autologous bone marrow transplantation in poor-risk Hodg-kin's disease. A single-center eight-year study of 155 patients", Blood, 81, 1137–1145.
   PubMed Web of Science ®Google Scholar
• Gribben, J.G., Linch, D.C., Singer, CR., McMillan, AK., Jarrett, M. and Goldstone, A.H. (1989) "Successful treatment of refractory Hodgkin's disease by high-dose combination chemotherapy and autologous bone marrow transplantation", Blood, 73, 340— 344.
   Google Scholar
• Horning, S.J., Chao, N.J., Negrin, R.S., Hoppe, R.T., Long, G.D., Hu, W.W., et al. (1997) "High-dose therapy and autologous hematopoietic progenitor cell transplantation for recurrent or refractory Hodgkin's disease: analysis of the Stanford University results and prognostic indices", Blood, 89, 801–813.
   Google Scholar
• Lazarus, H.M., Loberiza, FR., Jr., Zhang, M.J., Armitage, J.O., Ballen, K.K., Bashey, A., et al. (2001) "Autotransplants for Hodgkin's disease in first relapse or second remission: a report from the autologous blood and marrow transplant registry (ABMTR)", Bone Marrow Transplant, 27, 387— 396.
   Google Scholar
• Linch, D.C., Winfield, D., Goldstone, A.H., Moir, D., Hancock, B., McMillan, A., et al. (1993) "Dose intensification with autologous bone-marrow transplantation in relapsed and resistant Hodgkin's disease: results of a BNLI randomized trial", Lancet, 341, 1051 — 1054.
   PubMed Web of Science ®Google Scholar
• Sureda, A., Arranz, R., Iriondo, A., Carreras, E., Lahuerta, J.J., Garcia-Conde, J., et al. (2001) "Autologous stem-cell transplanta-tion for Hodgkin's disease: results and prognostic factors in 494 patients from the Grupo Espanol de Linfomas/Transplante Auto-logo de Medula Osea Spanish Cooperative Group", Journal of Clinical Oncology, 19, 1395 — 1404.
   Google Scholar
• Sweetenham, J.W., Carella, A.M., Taghipour, G., Cunningham, D., Marcus, R., Della, V.A., et al. (1999) "High-dose therapy and autologous stem-cell transplantation for adult patients with Hodgkin's disease who do not enter remission after induction chemotherapy: results in 175 patients reported to the European Group for Blood and Marrow Transplantation. Lymphoma Work-ing Party", Journal of Clinical Oncology, 17, 3101–3109.
   PubMed Web of Science ®Google Scholar
• Brice, P., Bouabdallah, R., Moreau, P., Divine, M., Andre, M., Aoudjane, M., et al. (1997) "Prognostic factors for survival after high-dose therapy and autologous stem cell transplantation for patients with relapsing Hodgkin's disease: analysis of 280 patients from the French registry. Societe Francaise de Greffe de Moelle", Bone Marrow Transplant, 20, 21— 26.
   PubMed Web of Science ®Google Scholar
• Smith, MR., Khanuja, P.S., Al-Katib, A., Bishop, CR., Andersen, J., Hussein, ME., et al. (1994) "Continuous infusion ABDIC therapy for relapsed or refractory Hodgkin's disease", Cancer, 73, 1264–1269.
   PubMed Web of Science ®Google Scholar
• Fleming, T.R. (1982) "One Sample multiple testing procedure for phase II clinical trials", Biometrics, 38, 143 — 151.
   Google Scholar
• Brice, P., Bastion, Y., Divine, M., Nedellec, G., Ferrant, A., Gabarre, J., et al. (1996) "Analysis of prognostic factors after the first relapse of Hodgkin's disease in 187 patients", Cancer, 78, 1293–1299.
   PubMed Web of Science ®Google Scholar
• Josting, A., Franklin, J., May, M., Koch, P., Beylcirch, M.K., Heinz, J., et al. (2002) "New prognostic score based on treatment outcome of patients with relapsed Hodgkin's Lymphoma registered in the database of the German Hodgkin's Lymphoma Study Group", Journal of Clinical Oncology, 20, 221–230.
   Google Scholar
• Lohri, A., Barnett, M., Fairey, RN., O'Reilly, SE., Phillips, G.L., Reece, D., et al. (1991) "Outcome of treatment of first relapse of Hodgkin's disease after primary chemotherapy: identification of risk factors from the British Columbia experience 1970 to 1988", Blood, 77, 2292–2298.
   Google Scholar
• Santoro, A., Viviani, S., Valagussa, P., Bonfante, V. and Bona-donna, G. (1986) "CCNU, etoposide, and prednimustine (CEP) in refractory Hodgkin's disease", Seminars in Oncology, 13, 23–26.
   Google Scholar
• Bonfante, V., Santoro, A., Viviani, S., Devizzi, L., Balzarotti, M., Soncini, F., et al. (1997) "Outcome of patients with Hodgkin's disease failing after primary MOPP- ABVD", Journal of Clinical Oncology, 15, 528 — 534.
   Google Scholar
• Lazarus, H.M., Rowlings, P.A., Zhang, M.J., Vose, J.M., Armitage, J.O., Bierman, P.J., et al. (1999) "Autotransplants for Hodgkin's disease in patients never achieving remission: a report from the Autologous Blood and Marrow Transplant Registry", Journal of Clinical Oncology, 17, 534— 545.
   Google Scholar
• Canellos, G.P., Anderson, J.R., Propert, K.J., Nissen, N., Cooper, M.R., Henderson, E.S., et al. (1992) "Chemotherapy of advanced Hodgkin's disease with MOPP, ABVD, or MOPP alternating with ABVD", New England Journal of Medicine, 327, 1478–1484.
   Google Scholar
• Viviani, S., Santoro, A., Negretti, E., Bonfante, V., Valagussa, P. and Bonadonna, G. (1990) "Salvage chemotherapy in Hodgkin's disease. Results in patients relapsing more than twelve months after first complete remission", Annals of Oncology, 1, 123–127.
   Google Scholar
• Brusamolino, E., Orlandi, E., Canevari, A., Morra, E., Castelli, G., Alessandrino, E.P., et al. (1994) "Results of CAV regimen (CCNU, melphalan, and VP-16) as third-line salvage therapy for Hodgkin's disease", Annals of Oncology, 5, 427 —432.
   Google Scholar
• Richards, M.A., Waxman, J.H., Man, T., Ganesan, T.S., Barnett, M.J., Wrigley, P.F., et al. (1986) "EVA treatment for recurrent or unresponsive Hodgkin's disease", Cancer Chemotherapy Pharma-cology, 18, 51 — 53.
   PubMed Web of Science ®Google Scholar
• Hagemeister, F.B., Tannir, N., McLaughlin, P., Salvador, P., Riggs, S., Velasquez, W.S., et al. (1987) "MIME chemotherapy (methyl-GAG, ifosfamide, methotrexate, etoposide) as treatment for recurrent Hodgkin's disease", Journal of Clinical Oncology, 5, 556–561.
   Google Scholar
• Rodriguez, J., Rodriguez, M.A., Fayad, L., McLaughlin, P., Swan, F., Sarris, A., et al. (1999) "ASHAP: a regimen for cytoreduction of refractory or recurrent Hodgkin's disease", Blood, 93, 3632— 3636.
   Google Scholar
• Moskowitz, C.H., Nimer, S.D., Zelenetz, A.D., Trippett, T., Hedrick, E.E., Filippa, D.A., et al. (2001) "A 2-step comprehensive high-dose chemoradiotherapy second-line program for relapsed and refractory Hodgkin disease: analysis by intent to treat and development of a prognostic model", Blood, 97, 616–623.
   Google Scholar
• Josting, A., Rudolph, C., Reiser, M., Mapara, M., Sieber, M., Kirchner, H.H., et al. (2002) "Time-intensified dexamethasone/ cisplatin/cytarabine: an effective salvage therapy with low toxicity in patients with relapsed and refractory Hodgkin's disease", Annals of Oncology, 13, 1628 — 1635.
   Google Scholar
• Martin, A., Fernandez-Jimenez, M.C., Caballero, M.D., Canales, M.A., Perez-Simon, J.A., Garcia, D.B., et al. (2001) "Long-term follow-up in patients treated with Mini-BEAM as salvage therapy for relapsed or refractory Hodgkin's disease", British Journal of Haematology, 113, 161–171.
   PubMed Web of Science ®Google Scholar
• Zinzani, P.L., Bendandi, M., Stefoni, V., Albertini, P., Gherlinzoni, F., Tani, M., et al. (2000) "Value of gemcitabine treatment in heavily pretreated Hodgkin's disease patients", Haematologica, 85, 926— 929.
   Google Scholar